First National Bank of Mount Dora Trust Investment Services lessened its stake in Merck & Co., Inc. (NYSE:MRK) by 17.4% in the first quarter, HoldingsChannel reports. The fund owned 48,673 shares of the company’s stock after selling 10,240 shares during the period. First National Bank of Mount Dora Trust Investment Services’ holdings in Merck & Co., Inc. were worth $3,752,000 at the end of the most recent quarter.
A number of other hedge funds also recently modified their holdings of MRK. Private Asset Management Inc. raised its position in Merck & Co., Inc. by 3.5% during the 1st quarter. Private Asset Management Inc. now owns 208,838 shares of the company’s stock valued at $16,099,000 after purchasing an additional 7,068 shares during the last quarter. Cox Capital Mgt LLC increased its stake in shares of Merck & Co., Inc. by 0.4% during the first quarter. Cox Capital Mgt LLC now owns 43,051 shares of the company’s stock valued at $3,319,000 after buying an additional 177 shares during the period. Red Spruce Capital LLC raised its holdings in shares of Merck & Co., Inc. by 11.6% during the first quarter. Red Spruce Capital LLC now owns 43,864 shares of the company’s stock valued at $3,381,000 after acquiring an additional 4,553 shares in the last quarter. M&R Capital Management Inc. lifted its stake in Merck & Co., Inc. by 560.2% in the first quarter. M&R Capital Management Inc. now owns 124,771 shares of the company’s stock worth $9,617,000 after acquiring an additional 105,872 shares during the period. Finally, Thomasville National Bank boosted its holdings in Merck & Co., Inc. by 2.8% in the first quarter. Thomasville National Bank now owns 51,966 shares of the company’s stock valued at $3,998,000 after acquiring an additional 1,433 shares in the last quarter. Institutional investors own 72.86% of the company’s stock.
Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Merck & Co., Inc. in a research report on Friday, February 5th. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $95.92.
Shares of NYSE:MRK traded up $0.07 during midday trading on Thursday, hitting $76.19. The company had a trading volume of 54,729 shares, compared to its average volume of 11,986,551. Merck & Co., Inc. has a 12-month low of $71.71 and a 12-month high of $87.80. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.30 and a quick ratio of 1.00. The company has a market cap of $192.78 billion, a price-to-earnings ratio of 16.84, a PEG ratio of 1.89 and a beta of 0.43. The company has a fifty day moving average of $75.36 and a two-hundred day moving average of $79.05.
Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Wednesday, February 3rd. The company reported $1.32 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.38 by ($0.06). The firm had revenue of $12.51 billion during the quarter, compared to the consensus estimate of $12.65 billion. Merck & Co., Inc. had a return on equity of 53.83% and a net margin of 24.33%. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.16 earnings per share. Research analysts expect that Merck & Co., Inc. will post 5.9 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Wednesday, April 7th. Shareholders of record on Monday, March 15th were issued a dividend of $0.65 per share. The ex-dividend date of this dividend was Friday, March 12th. This represents a $2.60 dividend on an annualized basis and a yield of 3.41%. Merck & Co., Inc.’s dividend payout ratio is presently 50.10%.
Merck & Co., Inc. Company Profile
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as and vaccine products.
Featured Story: What is a Stop Order?
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.